Zihua Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zihua Lin has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Chunmei Jing
Medicine Laboratory, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2nd Rd, 400014, Yuzhong, Chongqing, China
1 shared publicationJian Guo
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 Daxuecheng South Road, 401331, Shapingba, Chongqing, China
1 shared publicationQun Zhang
Medicine Laboratory, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2nd Rd, 400014, Yuzhong, Chongqing, China
1 shared publication- Shawn Chen
Global Health Drug Discovery Institute
1 shared publication Sheng Zhao
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 Daxuecheng South Road, 401331, Shapingba, Chongqing, China
1 shared publicationXiaobo Xu
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 Daxuecheng South Road, 401331, Shapingba, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 4 September 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-8
Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens
Development of effective antimicrobial agents continues to be a great challenge, particularly due to the increasing resistance of superbugs and frequent hospital breakouts. There is an urgent need for more potent and safer antibiotics with novel scaffolds. As historically many commercial drugs were derived from natural products, discovery of antimicrobial agents from complex natural product structures still holds a great promise. Herein, we report the total synthesis of natural albomycins δ1 (1a), δ2 (1b), and ε (1c), which validates the structures of these peptidylnucleoside compounds and allows for synthetic access to bioactive albomycin analogs. The efficient synthesis of albomycins enables extensive evaluations of these natural products against model bacteria and clinical pathogens. Albomycin δ2 has the potential to be developed into an antibacterial drug to treat Streptococcus pneumoniae and Staphylococcus aureus infections.
- 4 September 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-8
Open AccessTotal synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens
Development of effective antimicrobial agents continues to be a great challenge, particularly due to the increasing resistance of superbugs and frequent hospital breakouts. There is an urgent need for more potent and safer antibiotics with novel scaffolds. As historically many commercial drugs were derived from natural products, discovery of antimicrobial agents from complex natural product structures still holds a great promise. Herein, we report the total synthesis of natural albomycins δ1 (1a), δ2 (1b), and ε (1c), which validates the structures of these peptidylnucleoside compounds and allows for synthetic access to bioactive albomycin analogs. The efficient synthesis of albomycins enables extensive evaluations of these natural products against model bacteria and clinical pathogens. Albomycin δ2 has the potential to be developed into an antibacterial drug to treat Streptococcus pneumoniae and Staphylococcus aureus infections.